Enanta Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $65.3M-3.4% YoYTTM through 30 Sep 2025
Net Income -$81.9MTTM through 30 Sep 2025
Free Cash Flow -$24MTTM through 30 Sep 2025
Margins
| Current | |
|---|---|
| Operating Margin | -130.5% |
| Net Margin | -125.4% |
Returns
-108.0%ROE
-29.2%ROA
Balance Sheet Health
Debt / Equity0.00x
Net Debt-$47.1Knet cash position
Cash & Equivalents$188.9M
Quality Metrics
FCF Margin-36.7%
Earnings-Beat Rate100.0%
Dividend
No dividend
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Royalty Revenue | $65.3M | -3.4% | View detailsA portion (54.5%) of ongoing royalty revenue is paid to OMERS pursuant to a royalty sale transaction treated as debt, expected to continue through June 30, 2032. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.